// App-Quantinova.ai

OP0019 (2018) : Baricitinib in systemic lupus erythematosus (SLE: results from a phase 2, randomised, double-blind, placebo-controlled study

Researchers

Presenter

  • D.J. Wallace

Principal Investigators

  • R.A. Furie

  • Y. Tanaka

  • K.C. Kalunian

  • M. Mosca

  • M.A. Petri

  • T. Dorner

  • M.H. Cardiel

  • I.N. Bruce

  • E. Gomez

  • T. Carmack

  • J.M. Janes

  • M.D. Linnik

  • M. Silk

  • R. Hoffman

Medical Centers

  • Cedars-Sinai Medical Center, Los Angeles, CA

  • Hofstra Northwell School of Medicine, Medicine, New York, USA

  • University of Occupational and Environmental Health, Kitakyushu, Japan

  • University of California, San Diego School of Medicine, La Jolla, CA

  • Univ. of Pisa, Pisa, Italy

  • Johns Hopkins University School of Medicine, Baltimore, MD

  • Brustzentrum Charite-Universitatsmedizin, Berlin, Germany

  • Centro de Investigacion Clinica de Morelia, Morelia, Mexico

  • Univ of Manchester, Manchester

  • Eli Lilly and Company, Indianapolis, IN

Locations

  • United States

  • Japan

  • Italy

  • Germany

  • Mexico

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Lupus

  • Inflammatory Arthritis

Biomarkers

  • N/A

Drug/Treatment

  • Baricitinib

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Controlled

Phase

  • II

Study Id's

  • N/A

Sponsors

  • Mitsubishi Tanabe Pharma Corporation

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved